Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

Alnylam Pharmaceuticals said its RNAi therapeutic vutrisiran received a positive opinion recommending approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi ...

UK MHRA grants marketing authorization to Bayer’s acoramidis to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy: United Kingdom Monday, April ...

The following is a summary of “Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages,” published in the April 2025 issue of Journal of Neurology by ...

At present, there is no known cure for amyloidosis. However, advances in the understanding of amyloidosis have led to more treatment options and the possibility of a cure. Progression may be ...

Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage and weakened heart muscles related to a condition called ATTR amyloidosis. Amvuttra is given as an injection under ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis. Regardless of cutoffs, vutrisiran also improved various health and quality of life ...

Medical testing laboratory Dr. Lal PathLabs said on Tuesday that it has become south Asia’s first diagnostic chain to offer ...